• Trending
  • Latest
    Sign in Sign up
    • Log In
    • Register
    • Home
    • Discover
    • Experts
    • Home
    • Discover
    • Experts
    • Learning Lab
    • Home
    • Discover
    • Experts
    • Learning Lab
    • Mashup Score: 1
      Quirónsalud pone en valor la gestión de sus hospitales en la red pública - 2 year(s) ago

      La Fundación Jiménez Díaz, Rey Juan Carlos, Infanta Elena y General de Villalba han mostrado su evaluación de resultados

      Source: Redacción Médica
      Categories: Hem/Oncs, Latest Headlines
      Tweet Tweets with this article
      • Profile photo of 	DrRaulCordoba
        DrRaulCordoba

        RT @UICOquironsalud: ⁦@quironsalud⁩ pone en #valor la gestión de sus hospitales en la red pública #VBHC https://t.co/y8alfy4FNh

    • Mashup Score: 6
      U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III ObstructiveHypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms - 3 year(s) ago

      Camzyos is the first and only FDA-approved cardiac myosin inhibitor that specifically targets the source of obstructive HCM Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Camzyos™ (mavacamten, 2.5 mg, 5 mg, 10…

      Source: news.bms.com
      Categories: Cardiologists, Latest Headlines
      Tweet Tweets with this article
      • Profile photo of 	iamritu
        iamritu

        @EGarciaSayan @ASE360 @JournalASEcho @Kfarooqi @NadeenFaza @boegel_kelly @DavidWienerMD @docbhardwaj @ash71us @kgzimmerman @onco_cardiology mavacamten/Camzyos initiation & treatment will be serially #EchoFirst-guided — Rx will be restricted through REMS program https://t.co/QJ7GxU5u44 #Valor used core lab-measured LVEF, LVOT gradient at rest, & Valsalva provocation will this be sufficient in real world? #ASEchoJC

    • Mashup Score: 1
      Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice? - 3 year(s) ago

      Abstract. In less than 2 decades, major clinical advances have been made in various areas of hematologic malignancies. Clinicians and patients now frequently fa

      Source: American Society of Hematology
      Categories: Hem/Oncs, Latest Headlines
      Tweet Tweets with this article
      • Profile photo of 	DrRaulCordoba
        DrRaulCordoba

        #Hematología Este fue el trabajo que me hizo cambiar mi forma de entender la actividad asistencial hacia una “medicina basada en #valor”, dando voz al #paciente y haciéndolo partícipe en la toma de decisiones #VBHC #PROMs #PREMs https://t.co/q3OZnovlYb

      • Profile photo of 	DrRaulCordoba
        DrRaulCordoba

        #Hematology #PROMs may help to better understand over all treatment effectiveness and in making more informed, individualized treatment decisions in daily practice by obtaining information on the actual symptom burden experienced by the patient #VBHC https://t.co/q3OZnoMWPJ

    ASCO 2025

    Advertisement

    Advertisement

    MashupMD
    © 2025 - Mashup Media LLC
    • Terms of Use
    • Privacy Policy
    • Cookie Settings